David Micklem

3.5k total citations
59 papers, 2.7k citations indexed

About

David Micklem is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, David Micklem has authored 59 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 31 papers in Immunology and 26 papers in Molecular Biology. Recurrent topics in David Micklem's work include Phagocytosis and Immune Regulation (31 papers), Pancreatic and Hepatic Oncology Research (20 papers) and Chronic Lymphocytic Leukemia Research (7 papers). David Micklem is often cited by papers focused on Phagocytosis and Immune Regulation (31 papers), Pancreatic and Hepatic Oncology Research (20 papers) and Chronic Lymphocytic Leukemia Research (7 papers). David Micklem collaborates with scholars based in Norway, United States and United Kingdom. David Micklem's co-authors include James B. Lorens, Daniel St Johnston, Emmet McCormack, Catherine M. Davidson, Bjørn Tore Gjertsen, Andrea H. Brand, Tone Sandal, Crina Tiron, Lars A. Akslen and Hallvard Haugen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

David Micklem

54 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Micklem Norway 21 1.8k 623 531 271 227 59 2.7k
Jasper Mullenders Netherlands 17 2.0k 1.1× 651 1.0× 192 0.4× 157 0.6× 440 1.9× 25 2.7k
Tilman Borggrefe Germany 31 2.5k 1.4× 347 0.6× 464 0.9× 251 0.9× 388 1.7× 63 3.3k
Marc Lipinski France 28 1.8k 1.0× 306 0.5× 413 0.8× 165 0.6× 212 0.9× 67 2.6k
Nagesh Rao United States 26 1.3k 0.7× 400 0.6× 304 0.6× 121 0.4× 468 2.1× 74 2.3k
Peter Nollau Germany 25 1.2k 0.7× 825 1.3× 396 0.7× 318 1.2× 218 1.0× 48 2.5k
Emmanuelle Six France 23 1.4k 0.8× 358 0.6× 464 0.9× 228 0.8× 115 0.5× 35 2.0k
Ryo Iwamoto Japan 27 1.5k 0.9× 888 1.4× 616 1.2× 499 1.8× 242 1.1× 44 3.0k
Christof Fellmann United States 27 2.9k 1.6× 508 0.8× 221 0.4× 184 0.7× 455 2.0× 32 3.4k
Leo Kretzner United States 21 3.1k 1.7× 782 1.3× 285 0.5× 252 0.9× 297 1.3× 28 3.6k
Paul D. Kassner United States 23 945 0.5× 335 0.5× 651 1.2× 528 1.9× 261 1.1× 46 2.6k

Countries citing papers authored by David Micklem

Since Specialization
Citations

This map shows the geographic impact of David Micklem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Micklem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Micklem more than expected).

Fields of papers citing papers by David Micklem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Micklem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Micklem. The network helps show where David Micklem may publish in the future.

Co-authorship network of co-authors of David Micklem

This figure shows the co-authorship network connecting the top 25 collaborators of David Micklem. A scholar is included among the top collaborators of David Micklem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Micklem. David Micklem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Bhalla, Sheena, Farjana Fattah, Chul Ahn, et al.. (2023). Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 182. 107291–107291. 23 indexed citations
5.
6.
Bohan, Dana, Kai J. Rogers, José A. Aguilar-Briseño, et al.. (2021). Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathogens. 17(11). e1009743–e1009743. 75 indexed citations
7.
Arce‐Lara, Carlos, Edurne Arriola, Paal Brunsvig, et al.. (2018). P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S741–S741. 1 indexed citations
8.
Kirane, Amanda, Kathleen Ludwig, Noah Sorrelle, et al.. (2015). Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Research. 75(18). 3699–3705. 108 indexed citations
9.
Micklem, David, et al.. (2015). A new live-cell reporter strategy to simultaneously monitor mitochondrial biogenesis and morphology. Scientific Reports. 5(1). 17217–17217. 16 indexed citations
10.
Wergeland, Line, André Sulen, Vibeke Andresen, et al.. (2013). Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53null Cell Lines. PLoS ONE. 8(2). e56276–e56276. 26 indexed citations
11.
McCormack, Emmet, Richard M. West, Tina Pavlin, et al.. (2012). Nitroreductase, a Near-Infrared Reporter Platform for In Vivo Time-Domain Optical Imaging of Metastatic Cancer. Cancer Research. 73(4). 1276–1286. 37 indexed citations
12.
Blois, Anna, Crina Tiron, Monica Hellesøy, et al.. (2010). Efficient in vivo vascularization of tissue-engineering scaffolds. Journal of Tissue Engineering and Regenerative Medicine. 5(4). e52–e62. 48 indexed citations
13.
Evensen, Lasse, David Micklem, Wolfgang Link, & James B. Lorens. (2009). A novel imaging‐based high‐throughput screening approach to anti‐angiogenic drug discovery. Cytometry Part A. 77A(1). 41–51. 40 indexed citations
14.
Micklem, David, et al.. (2007). Drug target discovery using retroviruses. Expert Opinion on Drug Discovery. 2(10). 1285–1300. 2 indexed citations
15.
Bogenberger, Jakob, et al.. (2007). Expanding the Spectrum of Genetic Elements Transferable by Retroviral Vectors. DNA and Cell Biology. 26(11). 773–779. 2 indexed citations
16.
Micklem, David & James B. Lorens. (2007). RNAi Screening for Therapeutic Targets in Human Malignancies. Current Pharmaceutical Biotechnology. 8(6). 337–343. 18 indexed citations
17.
Ramos, Andres, Stefan Grünert, David Micklem, et al.. (2000). RNA recognition by a Staufen double-stranded RNA-binding domain. The EMBO Journal. 19(5). 997–1009. 297 indexed citations
18.
Micklem, David, Ramanuj DasGupta, Fanni Gergely, et al.. (1997). The mago nashi gene is required for the polarisation of the oocyte and the formation of perpendicular axes in Drosophila. Current Biology. 7(7). 468–478. 174 indexed citations
19.
Micklem, David. (1995). mRNA Localisation during Development. Developmental Biology. 172(2). 377–395. 59 indexed citations
20.
Fiering, Steven, Mario Roederer, Garry P. Nolan, et al.. (1991). Improved FACS‐Gal: Flow cytometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs. Cytometry. 12(4). 291–301. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jasper Mullenders Breakdown of academic impact, for papers by Tilman Borggrefe Breakdown of academic impact, for papers by Marc Lipinski Breakdown of academic impact, for papers by Nagesh Rao Breakdown of academic impact, for papers by Peter Nollau Breakdown of academic impact, for papers by Emmanuelle Six Breakdown of academic impact, for papers by Ryo Iwamoto Breakdown of academic impact, for papers by Christof Fellmann Breakdown of academic impact, for papers by Leo Kretzner Breakdown of academic impact, for papers by Paul D. Kassner
Rankless by CCL
2026